Secondary Prevention: Antiplatelets, Anticoagulation, Statins, and AF

The Mechanism-Driven Decision Tree

Secondary prevention reduces the risk of recurrent stroke after an index stroke or TIA — and recurrence risk is highest in the first days to weeks, so therapy starts early. The single most important question the SCRN must answer is: what was the mechanism? The answer routes the patient down one of two main pharmacologic paths.

• Noncardioembolic (large-artery atherosclerosis, small-vessel lacunar disease, cryptogenic) → antiplatelet therapy.
• Cardioembolic (most commonly atrial fibrillation) → anticoagulation.

Giving the wrong class is a high-yield trap: aspirin alone is inadequate for AF, while anticoagulating a small-vessel lacunar stroke adds bleeding risk without benefit. Every patient, regardless of mechanism, also needs a statin, blood-pressure control, glycemic control, and lifestyle/risk-factor modification — these "background" measures often deliver more absolute risk reduction than the antithrombotic choice itself.

Determining mechanism drives a standard secondary-prevention workup: vessel imaging (CT angiography, MR angiography, or carotid duplex) to find large-artery stenosis, prolonged cardiac monitoring to detect paroxysmal AF, and an echocardiogram to look for cardiac sources of embolism. A stroke labeled "cryptogenic" after a thorough evaluation is treated with antiplatelet therapy, but the nurse should anticipate extended rhythm monitoring because occult AF is a common hidden cause — and finding it converts the patient from antiplatelet to anticoagulation.

Antiplatelet Therapy and Short-Term DAPT

For noncardioembolic ischemic stroke or TIA, acceptable long-term single agents are aspirin 50–325 mg daily, clopidogrel 75 mg daily, or aspirin 25 mg + extended-release dipyridamole 200 mg twice daily. No single agent is clearly superior; choice balances tolerance, cost, and adherence.

The key tested nuance is dual antiplatelet therapy (DAPT). After a minor ischemic stroke (NIHSS ≤3) or a high-risk TIA (ABCD2 ≥4), the 2021 AHA/ASA guideline recommends starting aspirin + clopidogrel within 12–24 hours (and within 7 days) and continuing for 21 days, then dropping to single antiplatelet therapy. The 21-day limit exists because beyond about three weeks the bleeding risk outweighs benefit. The exception is symptomatic intracranial atherosclerotic disease (ICAD), where DAPT may be extended to ~90 days.

Continuing DAPT longer than 90 days, or using triple antiplatelet therapy, causes excess hemorrhage with no added benefit.

Anticoagulation for Atrial Fibrillation

For stroke caused by nonvalvular atrial fibrillation, anticoagulation is the standard. The CHA2DS2-VASc score quantifies risk; any patient who has already had a stroke/TIA scores at least 2 from that item alone, so essentially all AF stroke patients warrant anticoagulation.

DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for nonvalvular AF: fewer intracranial bleeds, no INR monitoring, and fewer interactions. Warfarin (INR 2–3) is required, however, for a mechanical heart valve or moderate-to-severe mitral stenosis — DOACs are contraindicated there. Timing of starting anticoagulation after an acute stroke balances recurrence against hemorrhagic transformation; larger infarcts wait longer (the informal "1-3-6-12 day" rule by severity).

Statins, Blood Pressure, and Carotid Revascularization

Statins: After an atherosclerotic ischemic stroke or TIA, high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20–40 mg) is indicated, targeting LDL <70 mg/dL. The SPARCL trial showed atorvastatin 80 mg cut recurrent stroke, and the Treat Stroke to Target trial confirmed an LDL goal <70 reduces recurrent cardiovascular events versus a higher target.

Blood pressure: After the hyperacute period, the long-term goal is generally <130/80 mm Hg; lowering BP is among the most effective recurrence-prevention measures. Thiazides, ACE inhibitors, and ARBs are common choices.

Carotid revascularization: For symptomatic (ipsilateral TIA/stroke) 70–99% internal carotid stenosis, carotid endarterectomy (CEA) is recommended when the perioperative stroke/death risk is <6%, ideally performed within 2 weeks of the event. CEA is also reasonable for symptomatic 50–69% stenosis in selected patients.

Carotid artery stenting (CAS) is an alternative, favored in patients at high surgical risk or with surgically inaccessible lesions, but carries a higher periprocedural stroke risk than CEA, especially in patients over 70. Near-occlusion or 100% (chronically occluded) vessels are generally not revascularized, because there is no longer a patent lumen to protect and the procedural risk outweighs benefit. Diabetes management, smoking cessation, and antiplatelet/statin therapy continue alongside any procedure.

Two final points round out secondary prevention. First, timing of anticoagulation after an acute cardioembolic stroke balances early recurrence against hemorrhagic transformation of the fresh infarct; the larger the infarct, the longer the wait, summarized informally as the "1-3-6-12 day" rule (TIA day 1, small stroke day 3, moderate day 6, large day 12). Second, lifestyle counseling is not optional — even a perfectly chosen drug regimen underperforms if the patient continues to smoke, eats a high-sodium diet, or remains sedentary.

The strongest exam answers pair the correct pharmacologic class with continued risk-factor control, because secondary prevention is a bundle, not a single pill.